MDACC Study No:2008-0005 ( NCT No: NCT00748215)
Title:Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients with Metastatic Colorectal Cancer
Principal Investigator:Bryan K. Kee
Treatment Agent:CASAD
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if calcium aluminosilicate
anti-diarrheal (CASAD) can help to control diarrhea in patients with metastatic
colorectal cancer who are receiving irinotecan. The safety of this drug will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Colorectal; Gastrointestinal
Phase of Study:Phase II
Treatment Agents:CASAD
Treatment Location:Both at MDACC & Community Programs (CCOP/Network)
Estimated Length of Stay in Houston:N/A
Supported By:NCI
Salient Pharmaceuticals Incorporated
Return Visit:Patients will be seen during their pre-treatment visits for irrinotecan therapy
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Bryan K. Kee
Dept:Community Oncology
For Clinical Trial Enrollment:713-563-0276
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults